HER2 Aptamer-Drug Complex for Targeted Chemotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods, such as chemotherapy and radiation therapy, face challenges with side effects and inefficacy in targeting HER2-positive breast cancer cells, particularly in delivering anticancer drugs effectively while minimizing harm to non-target regions.
Innovation Solution
A HER2 aptamer-anticancer drug complex is developed, utilizing a nucleic acid aptamer specifically binding to HER2 and linked with an anticancer drug via disulfide bonding, which is absorbed into cancer cells where glutathione breaks the bond, releasing the drug specifically within the cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat breast cancer, then cancer cells are killed by disturbing replication or metabolism, but side effects occur due to systemic chemotherapy affecting non-target cells
Solution Approach 1:
The chemotherapy approach is segmented into two distinct components: a targeting module (aptamer) that specifically binds to HER2-positive cancer cells, and a therapeutic module (anticancer drug) that kills cancer cells. This segmentation allows the drug to be delivered systemically while only exerting its toxic effect on the targeted cancer cells, thereby maintaining reliability while reducing harmful side effects on non-target cells.
Solution Approach 2:
The aptamer acts as an intermediary between the anticancer drug and the HER2-positive cancer cells. It mediates the specific recognition and binding to the target cells, enabling the drug to be selectively delivered to cancer cells rather than affecting all cells systemically. This intermediary function resolves the contradiction by providing specificity to an otherwise non-specific systemic treatment.
2Reliability
If radiation therapy is used to treat malignant tumors, then rapidly dividing cancer cells are destroyed, but normal tissue suffers weakness or loss of function
Solution Approach 1:
The therapy is segmented into a targeting component (aptamer binding to HER2) and a therapeutic component (anticancer drug). This allows the destructive action to be confined to only those cells expressing the HER2 target, preventing damage to normal tissue that does not express the target antigen.
Solution Approach 2:
The anticancer drug is delivered with local quality - it is concentrated specifically at the site of HER2-positive cancer cells through aptamer binding, rather than being uniformly distributed throughout the body. This localized delivery ensures that the destructive effect is confined to the target cells while sparing normal tissue.
3Manufacturing precision
If targeted therapy using aptamer-anticancer drug complex is developed, then specific delivery to HER2-positive cells is achieved, but complex formation and stability must be maintained
Solution Approach 1:
The complex stability is optimized by adjusting parameters such as aptamer sequence, drug-to-aptamer ratio, and linkage chemistry. These parameter changes allow the complex to remain stable during circulation and delivery while maintaining the ability to specifically bind to HER2-positive cells, thus achieving both manufacturing precision and compositional stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complex effectively targets and kills HER2-positive breast cancer cells, treats drug-resistant cases, and reduces side effects by ensuring the anticancer drug is released only within the cancer cells, enhancing apoptosis and tumor reduction.
Implementation Method 1
the complex absorbed into cancer cells is split by glutathione present in the cytosol
Data Source
AI summary
A method of manufacturing a complex for cancer cell chemotherapy comprises an aptamer preparation step of preparing a nucleic acid aptamer having an aptamer base sequence specifically binding to HER2, and a complex formation step of forming an aptamer-anticancer drug complex by reacting the aptamer prepared in the aptamer preparation step with an anticancer drug.